Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate is Used for managing HIV-1 infection in adults and pediatric patients aged 12 years and older. It was first introduced by Gilead Sciences Llc in its drug Atripla on Jul 12, 2006. 9 different companies have introduced drugs containing Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate.

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Patents

Given below is the list of patents protecting Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Atripla	US8598185	Unitary pharmaceutical dosage form	Apr 28, 2029	Gilead Sciences
Atripla	US9018192	Unitary pharmaceutical dosage form	Jun 13, 2026	Gilead Sciences
Atripla	US9545414	Unitary pharmaceutical dosage form	Jun 13, 2026	Gilead Sciences
Atripla	US8716264 (Pediatric)	Compositions and methods for combination antiviral therapy	Jul 03, 2024 (Expired)	Gilead Sciences
Atripla	US8592397	Compositions and methods for combination antiviral therapy	Jan 13, 2024 (Expired)	Gilead Sciences
Atripla	US8716264	Compositions and methods for combination antiviral therapy	Jan 13, 2024 (Expired)	Gilead Sciences
Atripla	US9457036	Compositions and methods for combination antiviral therapy	Jan 13, 2024 (Expired)	Gilead Sciences
Atripla	US9744181	Compositions and methods for combination antiviral therapy	Jan 13, 2024 (Expired)	Gilead Sciences
Atripla	US6703396 (Pediatric)	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	Sep 09, 2021 (Expired)	Gilead Sciences
Atripla	US6642245 (Pediatric)	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	May 04, 2021 (Expired)	Gilead Sciences
Atripla	US6703396	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	Mar 09, 2021 (Expired)	Gilead Sciences
Atripla	US6642245	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Nov 04, 2020 (Expired)	Gilead Sciences
Atripla	US6639071 (Pediatric)	Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one	Aug 14, 2018 (Expired)	Gilead Sciences
Atripla	US6939964 (Pediatric)	Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one	Jul 20, 2018 (Expired)	Gilead Sciences
Atripla	US6639071	Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one	Feb 14, 2018 (Expired)	Gilead Sciences
Atripla	US5922695 (Pediatric)	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability	Jan 25, 2018 (Expired)	Gilead Sciences
Atripla	US5935946 (Pediatric)	Nucleotide analog composition and synthesis method	Jan 25, 2018 (Expired)	Gilead Sciences
Atripla	US5977089 (Pediatric)	Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability	Jan 25, 2018 (Expired)	Gilead Sciences
Atripla	US6043230 (Pediatric)	Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability	Jan 25, 2018 (Expired)	Gilead Sciences
Atripla	US6939964	Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one	Jan 20, 2018 (Expired)	Gilead Sciences
Atripla	US5914331 (Pediatric)	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Jan 02, 2018 (Expired)	Gilead Sciences
Atripla	US5922695	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability	Jul 25, 2017 (Expired)	Gilead Sciences
Atripla	US5935946	Nucleotide analog composition and synthesis method	Jul 25, 2017 (Expired)	Gilead Sciences
Atripla	US5977089	Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability	Jul 25, 2017 (Expired)	Gilead Sciences
Atripla	US6043230	Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability	Jul 25, 2017 (Expired)	Gilead Sciences
Atripla	US5914331	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Jul 02, 2017 (Expired)	Gilead Sciences
Atripla	US5814639 (Pediatric)	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds	Mar 29, 2016 (Expired)	Gilead Sciences
Atripla	US5814639	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds	Sep 29, 2015 (Expired)	Gilead Sciences
Atripla	US5663169 (Pediatric)	Benzoxazinones as inhibitors of HIV reverse transcriptase	Mar 02, 2015 (Expired)	Gilead Sciences
Atripla	US5663169	Benzoxazinones as inhibitors of HIV reverse transcriptase	Sep 02, 2014 (Expired)	Gilead Sciences
Atripla	US5519021 (Pediatric)	Benzoxazinones as inhibitors of HIV reverse transcriptase	Nov 21, 2013 (Expired)	Gilead Sciences
Atripla	US5519021	Benzoxazinones as inhibitors of HIV reverse transcriptase	May 21, 2013 (Expired)	Gilead Sciences
Atripla	US5811423	Benzoxazinones as inhibitors of HIV reverse transcriptase	Aug 07, 2012 (Expired)	Gilead Sciences

Add above patents to watchlist

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate's Family Patents

Full family tree

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Generic API Manufacturers

Several generic applications have been filed for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. The first generic version for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate was by Aurobindo Pharma Ltd and was approved on Sep 4, 2018. And the latest generic version is by Mylan Pharmaceuticals Inc and was approved on Sep 5, 2024.

Given below is the list of companies who have filed for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate generic, along with the locations of their manufacturing plants worldwide.